Catalyst Biosciences has secured all rights to the manufacturing process for marzeptacog alfa (activated) (formerly known as CB 813d) from Wyeth LLC, a subsidiary of Pfizer. Marzeptacog alfa (activated) is a next-gen Factor VIIa designed to allow effective, long-term, subcutaneous prophylaxis in hemophilia patients with inhibitors. Catalyst has completed a Phase I trial of marzeptacog alfa (activated) in severe hemophilia A and B demonstrating the feasibility of subcutaneous dosing in preclinica...